Evidence for DNA damage checkpoint activation in barrett esophagus

Translational Oncology

Volumn 3, Issue 1, 2010, Pages 33-42

  Von Holzen, Urs ^a   Chen, Tina ^a   Boquoi, Amelie ^a   Richter, Joel E ^b   Falk, Gary W ^c   Klein Szanto, Andres J ^a   Cooper, Harry ^a   Litwin, Sam ^a   Weinberg, David S ^a   Enders, Greg H ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN A; ETOPOSIDE; HISTONE H3; HYDROXYUREA; NOCODAZOLE; PROTEIN P16; PROTEIN P53; PROTEIN YH2AX; TETRACYCLINE; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ESOPHAGUS; CELL CYCLE; CELL FRACTIONATION; CONFOCAL IMMUNOFLUORESCENCE; CONTROLLED STUDY; DISEASE COURSE; DNA DAMAGE; ENDOSCOPIC BIOPSY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PROTEIN INDUCTION; RISK ASSESSMENT;

EID: 77953427790     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09187     Document Type: Article

References (52)

1. Winters C Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF III, Johnson DA, Cruess DF, Cotelingam JD, Gurney MS, et al. (1987). Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92, 118-124.
2. Drewitz DJ, Sampliner RE, and Garewal HS (1997). The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 92, 212-215.
3. Dulai GS, Shekelle PG, Jensen DM, Spiegel BM, Chen J, Oh D, and Kahn KL (2005). Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol 100, 775-783.
4. Lagergren J, Bergstrom R, Lindgren A, and Nyren O (1999). Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340, 825-831.
5. Spechler SJ (2005). Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol 100, 927-935.
6. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, et al. (2009). Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 360, 2277-2288.
7. Kerkhof M, van Dekken H, Steyerberg EW, Meijer GA, Mulder AH, de Bruine A, Driessen A, ten Kate FJ, Kusters JG, Kuipers EJ, et al. (2007). Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 50, 920-927.
8. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H, et al. (1988). Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19, 166-178.
9. Finley JC, Reid BJ, Odze RD, Sanchez CA, Galipeau P, Li X, Self SG, Gollahon KA, Blount PL, and Rabinovitch PS (2006). Chromosomal instability in Barrett's esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev 15, 1451-1457.
10. Souza RF, Lunsford T, Ramirez RD, Zhang X, Lee EL, Shen Y, Owen C, Shay JW, Morales C, and Spechler SJ (2007). GERD is associated with shortened telomeres in the squamous epithelium of the distal esophagus. Am J Physiol Gastrointest Liver Physiol 293, G19-G24.
11. Halm U, Tannapfel A, Breitung B, Breidert M, Wittekind CW, and Mossner J (2000). Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma- sequence of Barrett's esophagus. Hepatogastroenterology 47, 962-966.
12. Lao-Sirieix P, Lovat L, and Fitzgerald RC (2007). Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin Cancer Res 13, 659-665.
13. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, and Reid BJ (1999). Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 91, 2087-2095.
14. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, and Reid BJ (2007). NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4, e67.
15. Reid BJ, Blount PL, and Rabinovitch PS (2003). Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 13, 369-397.
16. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, and Reid BJ (2005). Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6, 945-952.
17. Lai LA, Paulson TG, Li X, Sanchez CA, Maley C, Odze RD, Reid BJ, and Rabinovitch PS (2007). Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 46, 532-542.
18. Bartek J and Lukas J (2007). DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 19, 238-245.
19. Boquoi A, Jover R, Chen T, Pennings M, and Enders GH (2009). Transgenic expression of VEGF in intestinal epithelium drives mesenchymal cell interactions and epithelial neoplasia. Gastroenterology 136, 596-606.
20. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y, and Enders GH (2000). p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 119, 929-942.
21. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M, and Enders GH (1999). Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol 19, 3916-3928.
22. Zhou BB and Elledge SJ (2000). The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439.
23. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, et al. (2004). Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430, 797-802.
24. Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, Lowe SW, and Benezra R (2007). Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11, 9-23.
25. Goto H, Yasui Y, Nigg EA, and Inagaki M (2002). Aurora-B phosphorylates histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells 7, 11-17.
26. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, and Jackson SP (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198.
27. Kim ST, Lim DS, Canman CE, and Kastan MB (1999). Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 274, 37538-37543.
28. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER III, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, et al. (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166.
29. Jimenez GS, Khan SH, Stommel JM, and Wahl GM (1999). p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18, 7656-7665.
30. Furth EE, Gustafson KS, Dai CY, Gibson SL, Menard-Katcher P, Chen T, Koh J, and Enders GH (2006). Induction of the tumor-suppressor p16(INK4a) within regenerative epithelial crypts in ulcerative colitis. Neoplasia 8, 429-436.
31. 2 arrest after DNA damage. Science 282, 1497-1501.
32. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, and Abraham RT (1999). A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13, 152-157.
33. Vogelstein B, Lane D, and Levine AJ (2000). Surfing the p53 network. Nature 408, 307-310.
34. Keswani RN, Noffsinger A,Waxman I, and Bissonnette M (2006). Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 15, 1243-1249.
35. Lorinc E, Jakobsson B, Landberg G, and Veress B (2005). Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus. Histopathology 46, 642-648.
36. Segal F, Kaspary AP, Prolla JC, and Leistner S (2004). p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett's esophagus. Cancer Lett 210, 213-218.
37. Younes M, Ertan A, and Lechago J (2003). P53 protein and malignant progression in Barrett's metaplasia (Barrett's esophagus). Am J Gastroenterol 98, 1200-1201; author reply 1201.
38. Younes M, Ertan A, Lechago LV, Somoano JR, and Lechago J (1997). p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 42, 697-701.
39. Carlson N, Lechago J, Richter J, Sampliner RE, Peterson L, Santella RM, Goldblum JR, Falk GW, Ertan A, and Younes M (2002). Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am J Gastroenterol 97, 1340-1345.
40. 1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18, 378-387.
41. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, and Reid BJ (1996). Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 13, 1867-1873.
42. Gonzalez MV, Artimez ML, Rodrigo L, Lopez-Larrea C, Menendez MJ, Alvarez V, Perez R, Fresno MF, Perez MJ, Sampedro A, et al. (1997). Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 50, 212-217.
43. Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, et al. (2005). Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24, 4138-4148.
44. Klump B, Hsieh CJ, Holzmann K, Gregor M, and Porschen R (1998). Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 115, 1381-1386.
45. Maley CC and Rustgi AK (2006). Barrett's esophagus and its progression to adenocarcinoma. J Natl Compr Canc Netw 4, 367-374.
46. Merola E, Mattioli E, Minimo C, Zuo W, Rabitti C, Cicala M, Caviglia R, Pollice L, Gabbrielli A, Giordano A, et al. (2006). Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus. J Cell Physiol 207, 512-519.
47. Umansky M, Yasui W, Hallak A, Brill S, Shapira I, Halpern Z, Hibshoosh H, Rattan J, Meltzer S, Tahara E, et al. (2001). Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 20, 7987-7991.
48. Maude S and Enders G (2005). Cdk inhibition in human cells compromises Chk1 function and activates a DNA damage response. Cancer Res 65, 780-786.
49. Castell DO (2003). Does acid suppression alter progression in Barrett's esophagus? Am J Gastroenterol 98, 213-214; author reply 214.
50. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre M, Nuciforo PG, Bensimon A, et al. (2006).Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638-642.
51. Lord RV, O'Grady R, Sheehan C, Field AF, and Ward RL (2000). K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol 15, 730-736.
52. Olyaee M, Sontag S, Salman W, Schnell T, Mobarhan S, Eiznhamer D, and Keshavarzian A (1995). Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus. Gut 37, 168-173.